KD6001 is a humanized IgG1kappa monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNgamma expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer[1].
CAS Nummer:
[2983061-18-1]
Target-Kategorie:
CTLA-4
Anwendungsbeschreibung:
Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
